Microinjector Market Global Report 2026

The microinjector market size has grown rapidly in recent years. It will grow from $1.9 billion in 2025 to $2.15 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The historic growth was driven by growing demand for cell biology research, increasing use of in vitro fertilization procedures, expansion of genetic engineering research, rising investments in life science laboratories, and increasing adoption of micromanipulation techniques.

The microinjector market size is expected to see rapid growth in the next few years. It will grow to $3.49 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing demand for gene editing applications, rising investments in precision medicine research, growing adoption of advanced laboratory automation, expanding biotechnology research activities, and increasing development of regenerative medicine. Major trends in the forecast period include growing adoption of high-precision microinjection systems, increasing demand for automated micromanipulation workflows, rising development of multifunctional microinjectors, expansion of high-throughput laboratory injection platforms, and increasing focus on improving injection accuracy and reproducibility.

The increasing prevalence of infertility is expected to propel the growth of the microinjector market going forward. Infertility is a medical condition defined by the inability to achieve pregnancy after 12 months of regular unprotected intercourse or by difficulties in conceiving or carrying a pregnancy to live birth. The prevalence of infertility is rising due to delayed childbearing, as more individuals postpone parenthood until later reproductive years, when age-related declines in egg quality, ovarian reserve, and sperm health significantly reduce the likelihood of successful conception. Microinjectors support infertility treatment by enabling the precise injection of a single sperm directly into an egg during assisted reproductive procedures such as in vitro fertilization (IVF), thereby improving fertilization outcomes in cases of severe male-factor infertility. For instance, in April 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 17.5% of the adult population, or around 1 in 6 people worldwide, experience infertility, emphasizing the urgent need to improve access to affordable and high-quality fertility care. Therefore, the increasing prevalence of infertility is driving the growth of the microinjector market.

Major companies operating in the microinjector market are focusing on developing innovative solutions, such as automated robotic systems, to improve precision, increase efficiency, and minimize manual intervention in genetic research applications. Automated robotic systems are computer-controlled machines designed to perform tasks with high precision and minimal human involvement. For instance, in June 2025, Objective Biotechnology LLC, a US-based developer of next-generation laboratory automation tools, partnered with the University of Minnesota, a US-based public research university, and launched the Autoinjector, the first fully automated robotic system for microinjection in genetic research. The platform combines computer vision and machine learning to perform high-precision embryo injections up to four times faster than manual methods while significantly reducing technician training time. In addition, it supports large-scale genetic experiments, demonstrated by its capability to inject more than 20,000 uniquely barcoded DNA plasmids into Drosophila embryos within two days, generating hundreds of transgenic lines and improving vitrification and post-thaw survival rates in zebrafish compared to conventional methods.

In November 2023, BioCryst Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with Clearside Biomedical to develop avoralstat for the treatment of diabetic macular edema using Clearside’s proprietary SCS Microinjector. Through this partnership, BioCryst Pharmaceuticals Inc. and Clearside Biomedical aim to integrate a novel plasma kallikrein inhibitor therapy with a targeted suprachoroidal drug delivery system to improve treatment precision, enhance drug localization in the retina, and potentially provide an alternative therapeutic option for patients with diabetic macular edema who respond poorly to existing anti-VEGF therapies. Clearside Biomedical Inc. is a US-based company that provides the proprietary SCS Microinjector.

Major companies operating in the microinjector market are Thermo Fisher Scientific Inc., Sutter Instrument Company, Vitrolife AB, Harvard Bioscience Inc., Drummond Scientific Company, Applied Scientific Instrumentation (ASI), NEPA GENE Co Ltd., Prime Tech Ltd., World Precision Instruments, ALA Scientific Instruments Inc., Cook Medical LLC, LabSmith Inc., Luigs And Neumann GmbH, MicroData Instrument Inc., NPI Electronic GmbH, RWD Life Science Co Ltd., Sensapex Oy., Tritech Research Inc., Narishige Group, Eppendorf SE, Eppendorf Microdissection GmbH.

North America was the dominating region in the microinjector market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the microinjector market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.